article thumbnail

Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer

pharmaphorum

To be eligible for Libtayo patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumours must not have EGFR, ALK or ROS1 mutations. In this patient population, Libtayo reduced the risk of death by 32% compared to chemotherapy.

FDA 116
article thumbnail

FDA approves Regeneron’s Libtayo and chemotherapy combination for NSCLC

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Patients may receive this therapy regardless of PD-L1 expression or tumour histology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EC approves Regeneron’s Libtayo along with chemotherapy for NSCLC

Pharmaceutical Technology

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

article thumbnail

Intensity-modulated radiation therapy effective without chemotherapy in nasopharyngeal cancer

Hospital Pharmacy Europe

Currently, it is recommended that stage I disease is treated with radiotherapy alone whereas concurrent chemotherapy (i.e., Despite the recommendation to combine IMRT and chemotherapy for patients with stage II NPC, there is a lack of supportive evidence for this approach. chemoradiotherapy) is advised for patients at stage II.

article thumbnail

Kite releases pivotal CAR T therapy Phase III study results

European Pharmaceutical Review

Historical SOC involves platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy (HDT) and stem cell transplant (ASCT) in patients who respond to salvage chemotherapy. According to Kite, these findings will be presented in full later this year at an upcoming scientific meeting.

article thumbnail

AstraZeneca to acquire Fusion for approximately $2bn

Pharmafile

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn.

article thumbnail

Neoadjuvant nivolumab improves long-term survival for lung cancer

European Pharmaceutical Review

One patient experienced a recurrence within the first ten months post-treatment but has since been disease-free after definitive chemoradiation. Neoadjuvant nivolumab in combination with chemotherapy was approved by the US Food and Drug Administration (FDA) in March 2022 for lung cancer. It was successfully managed, the authors noted.